The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global healthcare chatbots market reached a value of US$ 207.36 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 711.07 Million by 2027, exhibiting at a CAGR of 21.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Healthcare chatbots are software integrated with machine learning (ML) algorithms and natural language processing (NLP). They allow medical assistants to stimulate and engage in conversations and provide real-time assistance to patients. They assist in reducing hospital visits, consultation times, unnecessary treatments and procedures, and hospital admissions and re-admissions by providing 24/7 remote medical care to patients. Nowadays, several healthcare chatbots are leveraged with complex self-learning algorithms to maintain in-depth, human-like conversations.
One of the significant factors driving the healthcare chatbots market is the coronavirus disease (COVID-19) outbreak. Due to the highly infectious nature of the virus, medical practitioners across the globe are relying on healthcare chatbots for monitoring patients with mild symptoms and providing hospital-based care on a timely basis. These chatbots communicate necessary information about COVID-19 in different languages and make the screening process faster and more efficient. Apart from this, the growing prevalence of chronic diseases, in confluence with the escalating demand for remote patient monitoring (RPM), is impelling the market growth. Moreover, private clinics are adopting healthcare chatbots to triage and clerk patients, which further leads to significant cost savings and improving patient care outcomes. They also aid in freeing up hospital resources for treating existing and critical patients. Besides this, several health firms are focusing on developing solutions that provide digital healthcare assistance. As a result, there is a rise in the usage of hybrid chatbots that provide an interface for patients to interact with real doctors via live videos or text consultation. Furthermore, these chatbots offer mental health assistance and cognitive-behavioral therapy (CBT) to people with post-traumatic stress disorder (PTSD), anxiety, or depression. They also help people with autism improve their social skills via webcams and microphones.
IMARC Group provides an analysis of the key trends in each sub-segment of the global healthcare chatbots market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on component, deployment mode, application and end user.
Breakup by Component:
Breakup by Deployment Mode:
Breakup by Application:
Breakup by End User:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Ada Health GmbH, Babylon Inc., Buoy Health Inc., Creative Virtual Ltd., GYANT.com Inc., HealthTap Inc., Infermedica, Microsoft Corporation, PACT Care BV, Sensely Inc., Woebot Health and Your.MD Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Component, Deployment Mode, Application, End User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Ada Health GmbH, Babylon Inc., Buoy Health Inc., Creative Virtual Ltd., GYANT.com Inc., HealthTap Inc., Infermedica, Microsoft Corporation, PACT Care BV, Sensely Inc., Woebot Health and Your.MD Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at